Sensorineural hearing loss (SNHL) is the most prevalent form of permanent hearing loss, affecting over 6% of the global ...

The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay ...

Sierra Leone’s President Julius Maada Bio was on Sunday elected Chairman of the Economic Community of West African States ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Researchers at the universities of Amsterdam and Utrecht have observed the formation of nanocavities in montmorillonite clay under exposure to ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.